Enhanced Communication Skills and C-reactive Protein Point-of-Care Testing for Respiratory Tract Infection: 3.5-year Follow-up of a Cluster Randomized Trial

Jochen W. L. Cals, MD, PhD1
Leon de Bock, MD1
Pieter-Jan H. W. Beckers, MD1
Nick A. Francis, MD, PhD2
Rogier M. Hopstaken, MD, PhD3
Kerenza Hood, PhD4
Eefje G. P. M. de Bont, MD1
Christopher C. Butler, MD2
Geert-Jan Dinant, MD, PhD4
1Department of General Practice, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, The Netherlands
2Institute of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff, United Kingdom
3Saltro Diagnostic Centre, Utrecht, The Netherlands
4South East Wales Trials Unit, School of Medicine, Cardiff University, United Kingdom

Conflicts of interest: Rogier Hopstaken has received travel/lecture funds from Axis-Shield (Norway) and Orion Diagnostica (Finland), both manufacturers of point-of-care C-reactive protein devices. All other authors declare no conflict of interest.

ABSTRACT

PURPOSE The purpose of the study was to assess the long-term effect of family physicians’ use of C-reactive protein (CRP) point-of-care testing and/or physician training in enhanced communication skills on office visit rates and antibiotic prescriptions for patients with respiratory tract infections.

METHODS We conducted a 3.5-year follow-up of a pragmatic, factorial, cluster-randomized controlled trial; 379 patients (20 family practices in the Netherlands) who visited their family physician for acute cough were enrolled in the trial and had follow-up data available (88% of original trial cohort). Main outcome measures were the average number of episodes of respiratory tract infections for which patients visited their family physician per patient per year (PPPY), and the percentage of the episodes for which patients were treated with antibiotics during follow-up.

RESULTS The mean number of episodes of respiratory tract infections during follow-up was 0.40 PPPY in the CRP test group and 0.56 PPPY in the no CRP test group ($P = .12$). In the communication skills training group, there was a mean of 0.36 PPPY episodes of respiratory tract infections, and in the no training group the mean was 0.57 PPPY ($P = .09$). During follow-up 30.7% of all episodes of respiratory tract infection were treated with antibiotics in the CRP test group compared with 35.7% in the no test group ($P = .36$). Family physicians trained in communication skills treated 26.3% of all episodes of respiratory tract infection with antibiotics compared with 39.1% treated by family physicians without training in communication skills ($P = .02$).

CONCLUSIONS Family physicians’ use of CRP point-of-care testing and/or training in enhanced communication skills did not significantly affect office visit rates related to respiratory tract infections. Patients who saw a family physician trained in enhanced communication skills were prescribed significantly fewer antibiotics during episodes of respiratory tract infection in the subsequent 3.5 years.

Ann Fam Med 2013;11:157-164. doi:10.1370/afm.1477.

INTRODUCTION

Respiratory tract infections are the most common reasons for acute care office visits and antibiotic prescribing in primary care.1,2 Reducing overprescribing of antibiotics for respiratory tract infections is essential in an era of increasing antimicrobial resistance.3 Important determinants influencing overprescription of antibiotics are patients’ expectations of antibiotics, physicians’ assumptions regarding these expectations, and physicians’ diagnostic uncertainty in differentiating serious from self-limiting disease.4,5 Differentiating those patients who are more likely to benefit from antibiotics from those who are unlikely to benefit is consid-
C-reactive protein (CRP) is a widely used and acknowledged marker to diagnose and monitor infections in secondary care. Diagnostic studies have emerged supporting the role of CRP testing in primary care as an additional diagnostic tool for managing lower respiratory tract infection. Robustness of the CRP point-of-care tests is now firmly established, with studies showing reliability and accuracy of test results obtained from office-based devices when compared with laboratory standards. A systematic review of the diagnostic role of CRP testing in lower respiratory tract infections in primary care showed that CRP levels were a strong predictor in differentiating pneumonia from acute bronchitis.

In 2 randomized trials including 688 primary care patients with respiratory tract infection, we were able to reduce antibiotic prescribing by family physicians exposed to communication skills training or through use of CRP point-of-care testing without adversely affecting patients' satisfaction or recovery. The major contribution of CRP point-of-care testing seems to be in decreasing physician uncertainty. To participating physicians we stressed that a CRP test result could add useful information in identifying those patients at low risk of a complicated illness course. We observed the greatest antibiotic prescribing reduction in patients with CRP levels of less than 20 mg/L. A cutoff value of 20 mg/L can be used to withhold antibiotic treatment in most patients with a low value (less than 75% of patients with lower respiratory tract infection in primary care). Patients with a CRP value higher than 100 mg/L (approximately 5% of patients) should receive antibiotics, whereas patients with intermediately elevated values ranging between 21 and 99 mg/L (20% of patients) should be carefully assessed based on the combination of medical history, physical examination, and CRP value, and a delayed prescription for antibiotics can be considered in selected cases.

The long-term effect of these interventions on medicalizing acute illness is unknown, however. For example, is has been suggested that point-of-care testing for common infections may promote help-seeking behavior for future similar symptoms. On the other hand, enhanced communication during the office visit may promote self-care, thus reducing future consulting in these patients. No study has so far measured the long-term effects of such interventions.

We therefore followed up a randomized trial cohort of 431 patients12 to determine long-term effects on physician visits and antibiotic prescriptions for patients after management by family physicians trained in enhanced communication skills and who used CRP point-of-care testing.

**METHODS**

Our study is a long-term follow-up of a pragmatic, factorial, cluster-randomized controlled trial assessing an illness-focused and a disease-focused intervention in the management of acute cough caused by lower respiratory tract infection in primary care. The initial trial evaluated the effect of family physicians' use of point-of-care CRP testing and physician communication skills training, both separately and combined, on antibiotic prescribing for lower respiratory tract infection. In the original trial, 431 adult patients with lower respiratory tract infection were enrolled by 40 Dutch family physicians from 20 family practices in the Southeastern part of the Netherlands. Practices were randomly assigned into 4 groups: (1) physician use of CRP testing, (2) physician communication skills training, (3) both interventions combined, and (4) usual care. Details of the interventions and study methods, including the exact inclusion criteria and the trial results, can be accessed elsewhere. Patients were recruited in the winter periods from September 2005 until March 2007 and were observed until July 2010. Thus, the current study focuses on the effects of the interventions on patients' subsequent office visit rates to their family physician for episodes of respiratory tract infection and associated antibiotic prescriptions for a 3.5-year follow-up period.

**Data Collection**

Patients in the Netherlands are registered with a single family physician, ensuring continuity of primary care medical records. We recorded episodes of respiratory tract infection leading to office visits from the end of the original 28-day follow-up period until July 1, 2010, by reviewing the medical records of the enrolled patients, which resulted in a follow-up period for every patient (follow-up period). We also recorded episodes of respiratory tract infection leading to office visits for the exact same period preceding the office visit in which the patient was recruited into the trial (baseline period). Consequently, the baseline period was of the same duration as the follow-up period for every patient, resulting in these definitions: the baseline period comprised the preintervention years (years before the trial); the follow-up period comprised the postintervention years (years after the trial).

Deceased patients were excluded. Similarly, patients who moved practices were excluded if their medical records could not be retrieved. If patients had changed practices but their medical records were still completely...
RESPIRATORY TRACT INFECTION MANAGEMENT

Outcomes
The primary outcome was the average number of episodes of respiratory tract infection during the follow-up period for which patients consulted their physician per patient per year (PPPY) and the proportion of these episodes that resulted in an antibiotic prescription.

Data Analysis
The 4 previously described groups were combined for analysis as follows: physician use of CRP testing (1 + 3) compared with no CRP test (2 + 4) (controlling for the effect of physician training in enhanced communication skills in the model), and physician training in enhanced communication skills (2 + 3) compared with no training (1 + 4) (controlling for the effects of CRP testing in the model).

Discrete variables were expressed as counts (percentages) and continuous variables as means (standard deviations), unless stated otherwise. Differences in baseline characteristics were assessed using the χ² test or Mann-Whitney test. Differences between physician office visit rates at baseline and office visit rates during follow-up in intervention and control arms were tested using Wilcoxon matched pairs signed rank test.

Episodes of respiratory tract infection per patient per year and the proportion of episodes resulting in an antibiotic prescription during baseline and follow-up were calculated with corresponding point estimates and 95% confidence intervals, as was the proportion of episodes that resulted in an antibiotic prescription.

The primary analysis compared the effect of intervention and control groups on episodes of respiratory tract infection and antibiotic prescriptions during follow-up. We used a multilevel linear regression model to account for variation at the level of family physician and to adjust for the other interventions, baseline number of episodes per patient per year or baseline antibiotic prescribing (as applicable), and 1 pre-defined variable (chronic obstructive pulmonary disease [COPD] comorbidity). An interaction effect was tested and excluded from analysis if not significant. Exploratory analyses investigating the influence of patients’ characteristics and interactions between the variables in the model were carried out as sensitivity analysis and included in the analysis if appropriate. Analysis was performed using SPSS 17.0 (SPSS Inc) and MLwiN 2.0 (Centre for Multilevel Modelling, University of Bristol).

The Ethics Committee of the Catharina Hospital in Eindhoven, the Netherlands (METC number M05-1529) approved the study.

RESULTS
Follow-up and Patient Characteristics
Of the original 431 patients enrolled in the trial, 379 patients (87.9%) had accessible medical records for the follow-up period and were included in the current analyses (203 in the CRP test group vs 176 in the no CRP test group, and 178 in the training in enhanced communication skills group vs 201 in the no training group). Fifty-two patients were excluded because their medical records were no longer available. Loss to follow-up rates ranged from 9.4% to 14.3% in the 4 groups. The flow chart (Figure 1) provides the reasons for exclusion. Recording periods were adjusted for another 54 patients because they moved from the practice. Data for analysis of the primary outcomes were available for all 379 patients.

Baseline characteristics of those patients included and those lost to follow-up for this study are shown in Table 1. Overall, the mean follow-up period was 3.67 years. Characteristics of patients in the intervention and control arms were comparable, except for antibiotic prescribing during the trial. Patients in the group of physicians using CRP testing and the group of physicians who had communication skills training were prescribed fewer antibiotics during the 28-day follow-up compared with patients in the control arms (Table 2), in line with the results of the original trial.12
At the index visit (the first visit in the original trial), 24 patients included for this follow-up study were given a diagnosis of COPD. During follow-up an additional 24 patients were given a diagnosis COPD, leading to a total of 48 patients with this condition.

**Office Visit Rates During Follow-up and Baseline Period**

Six hundred sixty-seven episodes of respiratory tract infection resulting in a total of 1,010 related office visits were registered in 379 patients (mean 1.51 office visits per episode) during follow-up. During the baseline period 586 episodes of respiratory tract infection led to a total of 881 related office visits (mean 1.50 office visits per episode).

Patients with COPD (n = 48, 12.7%) were responsible for 135 (23.0%) episodes and 188 (21.3%) related office visits at baseline and 221 (33.3%) episodes and 350 (34.7%) related office visits during follow-up.

The mean numbers of episodes of respiratory tract infection per patient per year in the intervention and control arms are reported in Supplemental Table 1, available at http://annfammed.org/content/11/2/157/suppl/DC1. We found an increase in episodes of respiratory tract infection during the follow-up period compared with the baseline period in the no CRP test group. After exclusion of COPD patients, this effect was no longer statistically significant.

**Effect of Interventions on Office Visits for Episodes of Respiratory Tract Infection and Associated Antibiotic Prescriptions**

We found no significant differences between intervention and control arms for episodes of respiratory tract
infection during follow-up (Table 3). The mean number of episodes during follow-up was 0.40 PPPY in the CRP test group, and 0.56 PPPY in the no CRP test group \((P = .12)\). The mean number of episodes in the communication skills training group and no training group were 0.36 PPPY and 0.57 PPPY, respectively \((P = .09)\).

Baseline antibiotic prescription rates per episode of respiratory tract infection were 40.7\% (95\% CI, 34.5\%-46.7\%) vs 34.1\% (95\% CI, 27\%, 8-40.3\%) in the CRP vs no CRP group and 34.5\% (95\% CI, 28.3\%-40.7\%) vs 40.4\% (95\% CI, 34.2\%-46.6\%) in the training vs no training group.

Table 4 shows the long-term effects of both interventions on antibiotic prescribing during follow-up in a multilevel linear regression model, adjusted for baseline prescribing, the other intervention, and COPD comorbidity. Patients managed by a physician who used a CRP point-of-care test received a prescription for antibiotics for 30.7\% of all episodes of respiratory tract infection for which they consulted at least once, whereas patients managed by a physi-

---

**Table 1. Baseline Characteristics of Study Patients and Comparison of Patients Followed up and Lost to Follow-up.**

| Characteristics                  | Patients in Original Trial N = 431 | Patients Available for Follow-up n = 379 | Patients Lost to Follow-up n = 52 | \(P\) Valuea |
|----------------------------------|-----------------------------------|----------------------------------------|-----------------------------------|--------------|
| Women, No. (%)                   | 265 (61.5)                        | 235 (62.0)                              | 30 (57.7)                         | .55          |
| Age, mean (SD), \(\gamma\)       | 49.9 (15.3)                       | 49.9 (15.0)                             | 49.8 (17.6)                       | .93          |
| Comorbidity at index visit, No. (%) |                                  |                                        |                                   |              |
| COPD                             | 31 (7.2)                          | 24 (6.3)                                | 7 (13.5)                          | .06          |
| Asthma                           | 39 (9)                            | 31 (8.2)                                | 8 (15.4)                          | .09          |
| Antibiotics prescribed, No. (%)  |                                   |                                        |                                   |              |
| At index visit of trial          | 178 (41.3)                        | 160 (42.2)                              | 18 (34.6)                         | .30          |
| During 28-day follow-up of trial | 221 (51.3)                        | 197 (52.0)                              | 24 (46.2)                         | .43          |

COPD = chronic obstructive pulmonary disease.

Note: data in this table represent information recorded during the index visit and 28-day follow-up of the original trial.

\(a\) \(P\) values come from Mann-Whitney test (age) or \(\chi^2\) test (other variables) comparing those available for follow-up with those lost to follow-up.

---

**Table 2. Characteristics of Patients With Complete Follow-up Data in Intervention and Control Arms**

| Characteristics                  | CRP Test \((n = 203)\) | No CRP Test \((n = 176)\) | \(P\) Valuea | Communication Skills Training \((n = 178)\) | No Communication Skills Training \((n = 201)\) | \(P\) Valuea |
|----------------------------------|------------------------|---------------------------|--------------|------------------------------------------|------------------------------------------------|--------------|
| Women, No. (%)                   | 119 (58.6)             | 116 (65.9)                | .15          | 118 (66.3)                               | 117 (58.2)                                      | .11          |
| Age, mean (SD), \(\gamma\)       | 49.4 (14.5)            | 50.4 (15.6)               | .53          | 51.0 (15.3)                              | 48.8 (14.6)                                     | .12          |
| Comorbidity, No. (%)             |                        |                           |              |                                         |                                                |              |
| COPD                             | 22 (10.8)              | 26 (14.8)                 | .23          | 20 (11.2)                                | 28 (13.9)                                       | .43          |
| Asthma                           | 27 (13.3)              | 28 (15.9)                 | .47          | 27 (15.2)                                | 28 (13.9)                                       | .73          |
| Antibiotics prescribed, No. (%)  |                        |                           |              |                                         |                                                |              |
| At index visit of trial          | 64 (31.5)              | 96 (54.5)                 | <.01         | 49 (27.5)                                | 111 (55.2)                                      | <.01         |
| During 28-day follow-up trial    | 92 (45.3)              | 105 (59.7)                | <.01         | 69 (38.8)                                | 128 (63.7)                                      | <.01         |

COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein.

Note: for the intervention arm, the family physician performed C-reactive protein testing or had communication skills training.

\(a\) \(P\) values come from Mann-Whitney test (age) or \(\chi^2\) test (other variables) comparing intervention group with no intervention group.

---

**Table 3. Respiratory Tract Infections During Follow-up in Intervention and Control Arms**

| RTI Episodes PPPY | Control Group Mean No. (95% CI) | Intervention Group Mean No. (95% CI) | Uncorrected Difference | Corrected Difference | \(P\) Valuea |
|------------------|---------------------------------|-------------------------------------|------------------------|----------------------|--------------|
| C-reactive protein test | 0.56 (0.43-0.68) | 0.40 (0.33-0.47) | -0.16 | -0.10 | .12 |
| Communication skills training | 0.57 (0.46-0.69) | 0.36 (0.30-0.42) | -0.21 | -0.11 | .09 |

COPD = chronic obstructive pulmonary disease; PPPY = per patient per year; RTI = respiratory tract infection.

Note: Intervention included point of care C-reactive protein testing or training in enhanced communication skills.

\(a\) \(P\) values from multilevel linear regression model to account and correct for variation at level of family physician, and to adjust for both interventions, the number of RTI episodes PPPY during baseline period, COPD comorbidity.
cian who did not use the test received a prescription for antibiotics for 35.7% of episodes ($P = .36$). Patients managed by a physician who had training in enhanced communication skills received an antibiotic prescription in 26.3% of all episodes during the 3.5 year follow-up, whereas patients managed by physician who did not have training in communication skills received a antibiotic prescription for 39.1% of all episodes ($P = .02$). The interaction term between the 2 interventions was not significant for illness episodes ($P = .17$) or antibiotic prescribing during follow-up ($P = .57$).

**Use of Tests and Serious Adverse Events**

During all follow-up years a CRP point-of-care test was only performed 11 times for 294 episodes of respiratory tract infection in the 203 patients in the CRP test group (3.7% of episodes). Of the 667 episodes of respiratory tract infection during follow-up of the 379 total study patients, 8 episodes (5 patients) led to hospital admission: 5 episodes (2 patients; 4 exacerbations of COPD and 1 case of pneumonia) in the usual care group, 1 episode (exacerbation of COPD) in the physician group that used CRP testing, and 2 episodes (pneumonia) in the combined intervention group.

**DISCUSSION**

**Summary and Main Findings**

A single office visit with a family physician who used a CRP point-of-care test and/or who had received training in enhanced communication skills had no effect on the rate of office visits for respiratory tract infection episodes during the subsequent 3.5 years. COPD patients showed an increase in frequency of office visits across all groups. Patients managed by a physician trained in enhanced communication skills were less likely to be prescribed antibiotics for episodes of respiratory tract infection for which they consulted during the 3.5-year follow-up. This long-term effect was not observed for CRP testing.

Concerns have been expressed about the potential medicalization of point-of-care testing in family practice.$^{17,18}$ We found, however, no evidence to suggest that the disease-focused intervention effect of a point-of-care test to rule out serious infection resulted in a subsequent increase in office visit rates. Additionally, giving patients evidence-based information by physicians trained in illness-focused communication skills could theoretically lead to fewer visits through increased patient self-management of future respiratory tract infections. We did observe a trend toward fewer visits for similar illness episodes; however, we did not observe a significant effect in this long-term follow-up study.

**Strengths and Weaknesses of the Study**

Using medical records to perform this follow-up study has limitations. To correct for differences in follow-up duration, we calculated the number of respiratory tract infection episodes per patient per year. By using this outcome measure, we can be confident that all patients were weighted equally in the analysis. We specifically chose an end date in July so the number of winter days in both periods would be similar. Seasonal and yearly differences in causative microorganisms could be a factor; however, one would expect effects on visits to be comparable across the groups.

We recognize the large interpractitioner variation in disease labeling for respiratory tract infection.$^{19}$ As a result, clear distinctions between visits for upper and lower respiratory tract infections were not presented. Additionally, in contrast to the original trial, we collected no physician or patient-recorded data on disease severity. We can therefore not judge whether visits related to respiratory tract infection were for self-limiting or more serious disease. Nonetheless, patients with respiratory tract infection, especially lower respiratory tract infection with a bothersome cough, often seek symptom relief and reassurance.$^{20}$ Given this limitation, we must be cautious in estimating the effect of the interventions on antibiotic prescribing during long-term follow-up. Nevertheless, it seems unlikely that the detected effect of communication skills training on antibiotic prescribing is a result of differences in the

---

**Table 4. Percentage of Episodes of Respiratory Tract Infection Treated With Antibiotics During Follow-up in Intervention and Control Arms**

|                      | Control Group | Intervention Group | Uncorrected Difference | Corrected Difference | $P$ Valuea |
|----------------------|---------------|--------------------|------------------------|----------------------|-----------|
| C-reactive protein test | 35.7 (29.5-42.0) | 30.7 (25.0-36.4) | -5.0                   | -4.1                 | .36       |
| Communication skills training | 39.1 (33.1-45.1) | 26.3 (20.6-32.0) | -12.8                  | -10.4                | .02       |

*Note: intervention included point-of-care C-reactive protein testing or training in enhanced communication skills.*

*a P values from multilevel linear regression model to account and correct for variation at the level of family physician, and to adjust for both interventions, RTI-episodes treated with antibiotics during baseline period, COPD comorbidity.*
range and severity of illness episodes, with visit rates in
general being unaltered in all groups.

With COPD, patients’ exacerbations are more
likely to occur with time as the severity of disease
increases. In our study, COPD patients (12.7%) were
responsible for approximately one-third of all visits
related to respiratory tract infection during follow-up.
It is quite unlikely that the observed increase in office
visit rate over time in this group was a result of either
of the interventions. The increase in office visits was
most prominent in the usual care group. To exclude
the influence of this chronic progressive disease, we
performed analyses for the primary outcomes correct-
foring for the diagnosis of COPD.

### Disease and Illness-Focused Approaches in Primary Care

By taking an illness-focused approach, accurate
communication between patient and physician can
improve the appropriateness of prescribing antibiotic,
particularly when the family physician is certain
of the diagnosis. When the physician is dealing with
diagnostic uncertainty, using point-of-care biomarkers
may be helpful in targeting inappropriate antibiotic
prescribing, as clinical judgment alone lacks specific-
ity in differentiating serious from mild infection.
Because an illness-focused intervention will appeal
to the patient’s interest, one would expect that solid
evidence-based information from the physician could
lower future office visit rates. Although we did not
find a significant effect, we observed a trend toward
fewer visits after seeing a family physician trained in
the use of advanced communication skills. The current
analysis may have been underpowered to detect a sig-
nificant effect, however.

We have no information about how often commun-
ication skills were used during follow-up. We previ-
osely reported sustained competence in implementing
these skills for a period of 6 months, and sustainable
uptake of the skills during the 2-year trial was high.
Although one could expect that evidence-based infor-
mation on the natural course and treatment of respira-
atory tract infection could lead to decreased visits for
similar episodes in the future, our current data do not
support this outcome. Yet, the wider applicability of
communication skills beyond lower respiratory tract
infection may explain reduced antibiotic prescribing
for respiratory tract infections by family physicians in
general. Communication skills training using an inter-
active booklet led to reductions in antibiotic prescrib-
ing for children, and a recent multifaceted educational
program that included online enhanced communication
skills training led to reductions in all-cause oral antibi-
otic dispensing during a 1-year follow-up period.

In contrast, a disease-focused intervention, such as
CRP testing, could increase the long-term likelihood
of patients consulting for similar illnesses in the future
(the so-called medicalization of self-limiting illness). In
Scandinavia, CRP testing at the point of care has been
widely introduced in primary care. The result has been
excessive use of CRP testing in these countries with
subsequent little value in accurately managing respira-
try tract infections. This outcome is in sharp contrast with
our findings, where the number of CRP measurements
during the entire follow-up period was very low—only
11 measurements in 203 patients. For patients in our
study, CRP testing did not specifically lead to increased
demand to be retested for similar future symptoms, nor
did the physicians who were exposed to the CRP test
start using it regularly with the same patient for different
illness episodes. These findings are consistent with pre-
vious qualitative findings of general physicians’ attitudes,
as well as national guidelines that recommend use of the
test only in cases of diagnostic uncertainty. In our
study, antibiotic prescribing rates during follow-up did
not differ between physicians regardless of whether they
were exposed to the test. It is possible that CRP point-
of-care testing is advocated for selected cases of lower
respiratory tract infection only and not for respiratory
tract infection in general. Outpatient antibiotic prescrib-
ing figures for the Netherlands are among the lowest in
Europe. Considering the effects on the interventions in
the Dutch setting with already low antibiotic prescrib-
ing rates, even larger effects could be expected in other
settings, as research shows that antibiotic prescribing for
acute cough varies widely across Europe.

Based on the effects of the interventions on short-
term antibiotic prescribing shown in the original trial,
and the lack of effect on long-term family physician
office visits, as shown in this follow-up study, imple-
mentation of both interventions on a larger scale can be
advocated. Training physicians in the use of enhanced
communication skills may have a wider long-term effect
on the treatment of respiratory tract infections beyond
acute cough to include reduced antibiotic prescribing.

To read or post commentaries in response to this article, see it
online at http://www.annfammed.org/content/11/2/157.

### Key words: respiratory tract infection; C-reactive protein; antibiotics;
communication; family practice

Submitted March 23, 2012; submitted, revised, July 24, 2012; accepted
August 8, 2012.

### Author contributions: All authors contributed to the design and
implementation of the study. Jochen Cals was responsible for running
the project. Pieter-Jan Beckers and Leon de Bock collected the follow-
up data in the practices and data analysis. Eefje de Bont assisted with
antibiotic prescribing data. All authors interpreted the data and findings
and all authors commented on the first draft and all further revisions.
Jochen Cals is guarantor for the paper. The corresponding author (J.W.L.C.) had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Funding support:** The Netherlands Organisation for Health Research and Development (ZonMW grant 945-04010) funded the trial. The South East Wales Trial Unit, which KH directs, receives funding from the National Institute for Health and Social Care (NISCHR).

**Disclaimer:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

**Previous presentation:** Findings from this study were presented at the GRIN (General Practice Respiratory Infection Network) conference, October 2011, Barcelona, Spain.

**Trial registration:** Current Controlled Trials ISRCTN85154857.

**Acknowledgments:** We thank the participating family physicians and patients.

**References**

1. Macfarlane J, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56(2):109-114.
2. Kuyvenhoven MM, van Balen FA, Verheij TJ. Outpatient antibiotic prescriptions from 1992 to 2001 in the Netherlands. J Antimicrob Chemother. 2003;52(4):675-678.
3. Nordberg P, Monnet DL, Cars O. Antibacterial Drug Resistance: Options for Concerted Action. Geneva : World Health Organization Department of Medicines Policy and Standards; 2005.
4. Butler CC, Kinnersley P, Prout H, Rollnick S, Edwards A, Elwyn G. Antibiotics and shared decision-making in primary care. J Antimicrob Chemother. 2001;48(3):435-440.
5. Little P, Dorward M, Warner G, Stephens K, Senior J, Moore M. Importance of patient pressure and perceived pressure and perceived medical need for investigations, referral, and prescribing in primary care: nested observational study. BMJ. 2004;328(7437):444.
6. Dinant GJ, Buntinx FF, Butler CC. The necessary shift from diagnostics to prognostic research. BMC Fam Pract. 2007;8:53.
7. Flanders SA, Stein J, Shochat G, et al. Performance of a bedside Creativ testing protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med. 2004;116(8):529-535.
8. Hopstaken RM, Muris JWM, Knootnerus JA, Kester ADM, Rinkens PELM, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate, and Creativ protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract. 2003;53(490):358-364.
9. Esposito S, Tremolari E, Begliatti E, Bosis S, Guatieri L, Principi N. Evaluation of a rapid bedside test for the quantitative determination of Creativ protein. Clin Chem Lab Med. 2005;43(4):438-440.
10. Seamark DA, Backhouse SN, Powell R. Field-testing and validation in a primary care setting of a point-of-care test for Creativ protein. Ann Clin Biochem. 2003;40(Pt 1):178-180.
11. van der Meer V, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of Creativ reactive protein in infections of the lower respiratory tract: systematic review. BMJ. 2005;331(7507):26-29.
12. Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for Creativ reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ. 2009;338:b1374.
13. Cals JW, Ament AJ, Hood K, et al. Creativ protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. J Eval Clin Pract. 2011;17(6):1059-1069.
14. Cals JW, Schot MJ, de Jong SA, Dinant GJ, Hopstaken RM. Point-of-care Creativ protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Ann Fam Med. 2010;8(2):124-133.
15. Cals JW, Hopstaken RM, Butler CC, Hood K, Severens JL, Dinant GJ. Improving management of patients with acute cough by Creativ protein point of care testing and communication training (IMPACT3): study protocol of a cluster randomised controlled trial. BMC Fam Pract. 2007;8:15.
16. Cals JW, Scheppers NA, Hopstaken RM, et al. Evidence based management of acute bronchitis; sustained competence of enhanced communication skills acquisition in general practice. Patient Educ Couns. 2007;68(3):270-278.
17. Hay AD, Jütterv KV. Antibiotics for acute cough in primary care. BMJ. 2009;338:b834.
18. Cals JW, Hood K, Aaftink N, et al. Predictors of patient-initiated reconsultation for lower respiratory tract infections in general practice. Br J Gen Pract. 2009;59(567):761-764.
19. Stocks N, Fahey T. Labelling of acute respiratory illness: evidence of between-practitioner variation in the UK. Fam Pract. 2002;19(4):375-377.
20. van Driel ML, De Sutter A, Deveugele M, et al. Are sore throat patients who hope for antibiotics actually asking for pain relief? Ann Fam Med. 2006;4(6):494-499.
21. Hurst JR, Perera WR, Wilkinson TMA, Donaldson GC, Wdziecha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(1):71-78.
22. Hopstaken RM, Stobberingh EE, Knottnerus JA, et al. Clinical items not helpful in differentiating viral from bacterial lower respiratory tract infections in general practice. J Clin Epidemiol. 2005;58(2):175-183.
23. Cals JW, Butler CC, Dinant GJ. ‘Experience talks’: physician prioritisation of contrasting interventions to optimise management of acute cough in general practice. Implement Sci. 2009;4:57.
24. Francis NA, Butler CC, Hood K, Simpson S, Wood F, Nuttall J. Effect of using an interactive booklet about childhood respiratory tract infections in primary care consultations on reconsulting and antibiotic prescribing: a cluster randomised controlled trial. BMJ. 2009;339:b2885.
25. Butler CC, Simpson SA, Dunstan F, et al. Effectiveness of multifaceted educational programme to reduce antibiotic dispensing in primary care: practice based randomised controlled trial. BMJ. 2012;344:d18173.
26. Engström S, Målstad S, Lindström K, Nilsson G, Borgquist L. Excessive use of rapid tests in respiratory tract infections in Swedish primary health care. Scand J Infect Dis. 2004;36(3):213-218.
27. Cals JW, Chappin FH, Hopstaken RM, et al. Creativ protein point-of-care testing for lower respiratory tract infections: a qualitative evaluation of experiences by GPs. Fam Pract. 2010;27(2):212-218.
28. Verheij T, Hopstaken R, Prins J, et al. NHG-Standaard Acuut hoesten. [Dutch College of General Practitioners Guidelines on Acute Cough]. Huisarts Wet. 2011;54(2):68-92.
29. Goossens H, Ferech M, Vander Stichele R, Elsevers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579-587.
30. Butler CC, Hood K, Verheij T, et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ. 2009;338:b2242.